netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.02.03  Expand sub section  Anti-lymphocyte monoclonal antibodies
Alemtuzumab (MabCampath®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

This is an NHS England Specialised Commissioning Drug for Multiple Sclerosis, Pre-transplant immunosuppression or CLL

 

MHRA advice (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements

 
Link  NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
   
Atezolizumab (Tecentriq®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  MHRA Drug Safety Update: Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
Link  NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
   
AvelumabBlack Triangle (Bavencio®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Link  NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma
   
Blinatumomab (Blincyto®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

NHS England specialist commissioning responsibility for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adults

 

 

 
Link  NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Link  NICE TA589:Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
   
CaplacizumabBlack Triangle (Cablivi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance

 
Link  NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
   
Dinutuximab (Qarziba®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

NHS England commissioned - hospital only

 

 
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
   
Gemtuzumab ozogamicin (Mylotarg®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

NHS England Commissioned - Hospital Only

 

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Inotuzumab ozogamicinBlack Triangle (Besponsa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

NHS England Commissioned - Hospital Only

 

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
   
IsatuximabBlack Triangle (Sarclisa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
   
NivolumabBlack Triangle (Opdivo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA advice (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation

 

 
Link  MHRA Drug Safety Update: Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Link  NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
   
Obinutuzumab  (Gazyvaro®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Link  NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
   
Ocrelizumab Black Triangle (Ocrevus®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

This is an NHS England specialised commissioning drug for MS

In line with NICE

 

This can only be prescribed if alemtuzumab is contraindicated or otherwise unsuitable.

 

 
Link  NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Link  NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
   
Ofatumumab (Arzerra®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
This is a Specialised Drug which would not be routinely commissioned by CCGs for Pemphigus vulgaris. This would go through a South Staffs CCGs Individual Funding Request (IFR)
 
Link  NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
Link  NICE TA344 : Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
   
Pembrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only
 

 

 
Link  MHRA Drug Safety Update: Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Link  NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Link  NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
   
Polatuzumab vedotinBlack Triangle (Polivy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
   
Cytotoxic Drug Rituximab iv (MabThera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

This is an NHS England Specialised Commissioning Drug for Cancer

 

 
Link  NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Link  NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Link  NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Link  NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Link  NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Link  NICE TA65: Non-Hodgkin’s lymphoma - rituximab
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  

Amber

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  

Amber E

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)   

Green

Suitable first-line drugs for implementation in Primary Care  

On Formulary

South Staffs Formulary Choice  

netFormulary